Bull case
Blueprint Medicines Corp demonstrates a robust growth potential, particularly with its flagship product, Ayvakit, which not only shows significant improvements in bone mineral density but is also forecasted to reach $2 billion in sales by 2030 due to increased market penetration in the systemic mastocytosis (SM) population. The projected expansion of the sales force in the second half of 2025 is expected to further enhance revenues starting 2026, while the existing commercial setup is anticipated to support growth even in 2025 through a deepened prescriber base and sustained patient satisfaction, with approximately 95% of patients reporting satisfaction with Ayvakit. Additionally, the development of promising drug candidates like BLU-808 and elenestinib may attract increased investor interest, reflecting strong long-term growth drivers within the company’s pipeline.